Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 with BCG or Gemcitabine in intermediate-risk NMIBC
NCT06829823Phase 2Not yet recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of nogapendekin alfa inbakicept in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Complete Response Rate at 6 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06829823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829823.